Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers release_bwhvj3moyvb7dlucjrlservu3a

by Klaudia Cybulska, Lars Perk, Jan Booij, Peter Laverman, Mark Rijpkema

Published in Molecules by MDPI AG.

2020   Volume 25, Issue 3, p482


Huntington's disease (HD) is a fatal neurodegenerative disease caused by a CAG expansion mutation in the huntingtin gene. As a result, intranuclear inclusions of mutant huntingtin protein are formed, which damage striatal medium spiny neurons (MSNs). A review of Positron Emission Tomography (PET) studies relating to HD was performed, including clinical and preclinical data. PET is a powerful tool for visualisation of the HD pathology by non-invasive imaging of specific radiopharmaceuticals, which provide a detailed molecular snapshot of complex mechanistic pathways within the brain. Nowadays, radiochemists are equipped with an impressive arsenal of radioligands to accurately recognise particular receptors of interest. These include key biomarkers of HD: adenosine, cannabinoid, dopaminergic and glutamateric receptors, microglial activation, phosphodiesterase 10 A and synaptic vesicle proteins. This review aims to provide a radiochemical picture of the recent developments in the field of HD PET, with significant attention devoted to radiosynthetic routes towards the tracers relevant to this disease.
In application/xml+jats format

Archived Files and Locations

application/pdf  1.3 MB
file_hqxdnqovfzamrfy4b3ucy2jbba (webarchive) (publisher)
Read Archived PDF
Type  article-journal
Stage   published
Date   2020-01-23
Language   en ?
Container Metadata
Open Access Publication
In Keepers Registery
ISSN-L:  1420-3049
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: b811bb59-a114-4d00-8b42-f75d835d66f1